ACAD

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD - Research Report) today and set a price target of $25.00. The company's shares closed yesterday at $15.93.According to TipRanks, Fein is an analyst with an average return of -11.3% and a 33.26% success rate. Fein covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Matinas BioPharma, and Wave Life Sciences.Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $19.45, a 22.10% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $24.00 price target.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral